AlphaMeld Corporation
Somdatta Sen, Ph.D., is a Senior Scientific Analyst at InveniAI since March 2022, previously serving as a Research Analyst at The Gene Box from September 2021 to March 2022. Somdatta's academic background includes a Ph.D. scholarly work at NIMHANS from December 2012 to November 2019, along with roles as a Senior Research Fellow and Junior Research Fellow at the same institution. Educational qualifications include an MSc in Biomedical Genetics from Vellore Institute of Technology and a BSc in Human/Medical Genetics and Applied Genetics from Ramaiah College of Arts Science and Commerce and Bangalore University, respectively.
Previous companies
This person is not in any offices
AlphaMeld Corporation
Headquartered in Guilford, CT, AlphaMeld® Corporation (a wholly owned subsidiary of InveniAI LLC) stands as a global frontrunner in the application of AI, machine learning, and generative AI tools, catalyzing innovation throughout drug discovery and development. With a mission to identify and expedite transformative therapies for diseases with unmet medical needs, the company utilizes its cutting-edge AlphaMeld platform to extract valuable insights from petabytes of diverse data sets, propelling the creation of groundbreaking drug programs. The company's pioneering approach is underscored by successful collaborations with industry leaders and drug spinouts, solidifying its position as a trailblazer in the realm of AI-driven drug discovery. About The AlphaMeld® Platform The AlphaMeld platform employs a comprehensive approach to generate testable hypotheses, considering factors such as the ideal mode of pharmacotherapy, disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies. This is done while factoring in medical, scientific, strategic, and commercial considerations.